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Summary
Background Suboptimal diagnostics for pulmonary tuberculosis drive the use of the so-called trial of antibiotics, a 
course of broad-spectrum antibiotics without activity against Mycobacterium tuberculosis that is given to patients who 
are mycobacteriology negative but symptomatic, with the aim of distinguishing pulmonary tuberculosis from 
bacterial lower respiratory tract infection. The underlying assumption—that patients with lower respiratory tract 
infection will improve, whereas those with pulmonary tuberculosis will not—has an unclear evidence base for such a 
widely used intervention (at least 26·5 million courses are prescribed per year). We aimed to collate available evidence 
on the diagnostic performance of the trial of antibiotics.
Methods In this systematic review and meta-analysis we searched the MEDLINE, Embase, and Global Health 
databases for studies published up to March 15, 2019, that investigated the sensitivity and specificity of the trial of 
antibiotics against mycobacteriology tests in adults (≥15 years) with tuberculosis symptoms. We used the QUADAS-2 
tool to assess the risk of bias. We estimated pooled values for sensitivity and specificity of trial of antibiotics (as the 
index text) versus mycobacteriology tests (as the reference standard) using random-effects bivariate modelling, and 
we used the I² statistic to assess heterogeneity between studies contributing to these estimates. This study is registered 
with PROSPERO, number CRD42017083915.
Findings Of the 9410 articles identified by our search, eight studies were eligible for inclusion. The studies were from 
seven countries in Africa, South America, and Asia, and involved 2786 participants. Six studies used mycobacterial 
culture as the reference standard, and six used penicillins for the trial of antibiotics. The treatment duration, number 
of antimicrobial courses, and definition of what constituted response to treatment varied substantially between 
studies. The pooled sensitivity (67%, 95% CI 42–85) and specificity (73%, 58–85) of the trial of antibiotics 
versus mycobacteriology tests were below internationally defined minimum performance profiles for tuberculosis 
diagnostics and had substantial heterogeneity (I² was 96% for sensitivity and 99% for specificity). Each included study 
failed on one or more domain of the QUADAS-2 tool.
Interpretation Current policy and practice regarding the trial of antibiotics appear inappropriate, given the weak 
evidence base, poor diagnostic performance, potential contribution to the global antimicrobial resistance crisis, and 
adverse individual and public health consequences from the misclassification of tuberculosis status. Antibiotic 
strategies during tuberculosis investigations should instead optimise clinical outcomes, ideally guided by clinical 
trials in both inpatient and outpatient groups.
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Introduction
Tuberculosis is the leading cause of adult mortality due to 
infectious disease, with 10 million new cases and 
1·6 million deaths annually,1 but it is curable when 
correctly diagnosed in a timely manner. However, current 
diagnostics are suboptimal, missing many cases.2 
Recognising the limitations of current diagnostic tests, 
the standard diagnostic algorithms that are endorsed by 
WHO3,4 and that have been routinely promoted by national 
tuberculosis programmes5 include the level of response 
to a course of broad-spectrum antibiotics as a means 
of excluding (or including) tuberculosis as a cause of 
symptoms. The course of broad-spectrum antibiotics, 
commonly referred to as a trial of antibiotics, has 
negligible activity against Mycobacterium tuberculosis 
(MTB) and is given to symp tomatic patients with negative 
sputum myco bacteriology (panel, appendix pp 3–4).6 
Patients with negative sputum mycobacteriology whose 
symptoms res pond to the antibiotic treatment are 
considered tuber culosis negative, whereas those who 
remain symptomatic are deemed in need of further 
evaluations, potentially leading to tuber culosis treatment.6,7
We estimated conservatively that at least 26·5 million 
courses of antibiotics are prescribed in the course 
of diagnosing 5·3 million smear-negative tuberculosis 
registrations per year, which raises concerns about the 
See Online for appendix
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contributions of this practice to antimicrobial resistance.8 
This estimate assumes an average of five antibiotic 
courses per treatment initiation for a sputum-negative 
patient, including two courses given to the patient before 
tuberculosis treatment and three more given when 
tuberculosis is ruled out by the patient’s response to 
antibiotics.5,7 Despite the widespread use of the trial of 
antibiotics, no systematic review has focused on its 
diagnostic performance.
Other important evidence gaps concern the choice of 
antibiotics for the trial of antibiotics (except for the advice 
to avoid those with known anti-tuberculosis activity), the 
duration of treatment, the number of antibiotic trials, 
and the definition of treatment response. The inadequate 
consolidation of evidence in these areas is reflected in 
pronounced variations in how the trial of antibiotics is 
implemented across national programmes.5
The poor evidence on the use of the trial of antibiotics is 
also reflected in WHO recommendations, which evolved 
from bold recommendation of a routine trial of antibiotics 
in 19973 to more cautious language in 2018.4 The 
1997 WHO guidelines3 included the absence of a clinical 
response after 1 week of broad-spectrum antibiotics as 
part of the case definition for smear-negative tuberculosis. 
10 years later, in 2007, the guidelines for people living with 
HIV or AIDS called for more research into the diagnostic 
benefit of the trial of antibiotics and recommended 
that the primary role of antibiotics should not be as a 
diagnostic aid but as treatment for concomitant bacterial 
infection.9 After another decade, and in the context of 
growing concern about antimicrobial resis tance, the 
2018 WHO model algorithms still support the trial of 
antibiotics (appendix p 3).4 In practice, national guidelines 
and routine clinical practice in low-income settings still 
follow the 1997 approach to the trial of antibiotics 
(appendix p 4).
The objective of this systematic review was to assess 
existing evidence for the diagnostic accuracy (sensitivity 
and specificity) of the trial of antibiotics compared with 
sputum mycobacteriology tests for the diagnosis of 
tuberculosis. We also describe the choice of antibiotic, 
duration of treatment, and definition of post-treatment 
improvement.
Methods
Search strategy and selection criteria
For this systematic review and meta-analysis, we 
searched MEDLINE, Embase, and Global Health using 
the Ovid platform for studies published up to 
March 15, 2019, when the search was run. The search 
strategies are described in the appendix (pp 1–2). We 
included all studies published in any language that 
included adults (≥15 years) who were being investigated 
for pulmonary tuberculosis, which reported outcomes 
of both a trial of antibiotics and mycobacteriology investi-
gations as part of a standardised diagnostic work-up. 
Research in context
Evidence before this study
Antimicrobial resistance and tuberculosis are both serious threats 
that together cause 2·5 million deaths each year, are part of the 
2030 agenda for sustainable development, and are two of only 
five health issues to ever secure a dedicated United Nations High 
Level Meeting. Apart from drug-resistant tuberculosis, a less 
discussed but key overlap between these two threats is that tens 
of millions of doses of broad-spectrum antibiotics are used in the 
diagnostic work-up for tuberculosis, with the so-called trial of 
antibiotics probably being the most used tuberculosis diagnostic 
globally. The trial of antibiotics reflects the suboptimal nature of 
current tuberculosis diagnostics, which miss a substantial fraction 
of tuberculosis cases. The underlying assumptions are that 
symptoms that respond to antibiotics are attributable to other 
respiratory infections (assumed to be sensitive to the broad-
spectrum antibiotic used), whereas non-responsive symptoms 
are likely to be due to tuberculosis.
Two previous systematic reviews documented the role of 
broad-spectrum antibiotics in the diagnosis of tuberculosis, 
although neither addressed their specific diagnostic value. 
The scarcity of evidence in this area was first highlighted in 
the 2007 WHO guidelines on tuberculosis diagnosis in HIV-
prevelant and low-resource settings, which recommended the 
use of antibiotics in patients with HIV to treat presumptive 
bacterial infections, but not for diagnostic purposes. The 2018 
WHO recommendations, however, retain response to antibiotic 
treatment as a key part of clinical evaluation of patients both 
with and without HIV following a negative Xpert MTB/Rif test.
Added value of this study
To our knowledge, this is the first systematic review and 
meta-analysis, and the most comprehensive assessment, of the 
performance of the trial of antibiotics in tuberculosis diagnostic 
algorithms. Our study shows little evidence to support the 
continued implementation of the trial of antibiotics. 
The available studies are few in number, of poor quality, and do 
not use standardised methodologies, leading to high interstudy 
heterogeneity. The pooled sensitivity (67%, 95% CI 42–85; 
I²=96%) and specificity (73%, 58–85; I²=99%) of the trial of 
antibiotics versus sputum mycobacteriology were both below 
internationally defined minimum performance profiles for 
tuberculosis diagnostics.
Implications of all the available evidence
The trial of antibiotics, despite being part of global 
recommendations for over three decades, has yet to be 
supported by evidence. The poor diagnostic performance, 
potential to increase antimicrobial resistance, and public health 
consequences of the misclassification of tuberculosis status 
warrant urgent and well designed prospective trials.
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Acceptable study designs were cross-sectional, cohort, or 
randomised controlled trials. To be eligible, studies had 
to recruit adults on the basis of symptoms suggestive 
of tuberculosis (with or without a preceding chest 
radiograph), include a trial of antibiotics as the index test 
and any sputum-based mycobacteriology test as the 
reference test, and report the proportions of participants 
whose mycobacteriology tests were positive or negative 
who were correctly or incorrectly identified through a 
trial of antibiotics (ie, both sensitivity and specificity).
The protocol for this systematic review, including 
detailed methods, is published elsewhere.10 This 
study is registered with the International Prospective 
Register of Systematic Reviews (PROSPERO), registration 
number CRD42017083915. We prepared our study 
protocol, performed the systematic review, and prepared 
the report according to recommendations by the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA).11
Data extraction
Two reviewers independently screened the titles and 
abstracts of the articles identified through the electronic 
searches against the eligibility criteria: THD and MN 
assessed articles published from Jan 1, 1993, to 
March 15, 2019; and on Aug 6, 2019, following the advice of 
a peer reviewer, THD and CK assessed all articles indexed 
by the selected databases up to Dec 31, 1992. THD, MN, 
and CK independently assessed the full texts of the 
included papers, documented the reasons for non-
inclusion, and identified additional articles from reference 
lists. KLF resolved disagreements in eligibility. Huan 
Zhang and Mengyun Liu (London School of Hygiene & 
Tropical Medicine, London, UK) inde pendently assessed 
the full texts of Chinese-language articles. THD, MN, and 
CK extracted data from the eligible articles into an Excel 
database and resolved discrepancies by consensus.
The following data were extracted from eligible papers: 
first author, year of publication, country of data collection, 
antibiotics used for the trial of antibiotics, duration 
of antibiotic treatment, method of assessing response to 
antibiotic treatment, reference mycobacteriology tests, and 
number of patients given both a trial of antibiotics and a 
mycobacteriology reference test. Articles were defined as 
eligible for meta-analysis estimation of sensitivity and 
specificity if they provided data on numbers of patients 
that were true positives, false positives, false negatives, and 
true negatives. For studies with missing or incomplete 
information for the meta-analysis, we contacted the 
authors for data. In cases where data were unavailable, we 
included in narrative synthesis as much information as the 
study could provide.
Assessment of study bias
We assessed risk of bias at the level of the study using 
QUADAS-2 (University of Bristol, Bristol, UK), the 
recommended tool for evaluating primary studies for 
inclusion in systematic reviews involving assessment 
of diagnostic accuracy.12 We assessed the risk of bias 
and applicability concerns using four domains: patient 
selection, index test, reference standard, and patient flow 
and timing of tests. The level of risk or concern was 
reported as either high, low, or unclear.
Meta-analysis
We included in the meta-analysis all studies that provided 
data that allowed us to calculate sensitivity and specificity 
of a trial of antibiotics against a reference standard of 
myco bacteriology tests. The meta-analysis was done 
using MIDAS (version 15.0),13 which uses joint modelling 
of sensitivity and specificity. We estimated point esti-
mates and 95% CIs for sensitivity and specificity for each 
study and for pooled data using bivariate random effects 
modelling.
To provide an inference of diagnostic quality, we plotted 
a summary receiver operating characteristic curve, in 
which the diagnostic accuracy of the trial of antibiotics 
was estimated by the area under the curve and the 
summary operating point.
We assessed heterogeneity across studies using the 
I² statistic, and we used a bagplot to examine the spread 
of the observed data and identify outliers. We examined 
clinical utility of trial of antibiotics using a Fagan plot, and 
we used the Deeks funnel plot to identify evidence of 
publication bias in studies of diagnostic performance.
Panel: Antibiotics as diagnostics for tuberculosis
Tuberculosis should be investigated in all patients presenting 
with respiratory symptoms using sputum-based tuberculosis 
diagnostic tests (smear microscopy or Xpert MTB/Rif). 
However, negative results on these tests do not rule out 
tuberculosis. The 2018 WHO model diagnostic algorithm 
(appendix p 3) advises clinical re-evaluation of patients with 
negative sputum results, with suggestions of “chest X-ray, 
additional clinical assessments, clinical response following 
treatment with broad-spectrum antimicrobial agents, repeat 
Xpert MTB/RIF testing, or culture”.4 Of these options, clinical 
response to broad-spectrum antimicrobial agents, the 
so-called trial of antibiotics, has long been the priority for 
national programmes in resource-limited settings 
(appendix p 4).
The trial of antibiotics serves two distinct goals: first, to 
empirically treat bacterial respiratory tract infections 
using one or more antibiotics with minimal or no 
anti-mycobacteriological activity; and second, to use the 
response to treatment to determine the need for further 
tuberculosis investigations, assuming that illness due to 
active tuberculosis will not respond. The focus of this 
systematic review is on the second diagnostic goal, 
whereby a trial of antibiotics is used to distinguish 
tuberculosis from other infectious causes of respiratory 
illness.
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We did subgroup and sensitivity analyses. For the 
subgroup analysis, we used univariate meta-regression. 
Our a-priori subgroups were study setting (whether a 
study was done in sub-Saharan Africa) and reference test 
(whether the study used MTB culture as the reference 
standard). In a post-hoc analysis, we stratified the data by 
use of chest radiography (in addition to tuberculosis 
symptoms) for pre-screening. For the sensitivity analyses, 
we restricted the meta-analysis to high-quality studies 
(showing high risk of bias in no more than one domain 
of QUADAS-2).
Role of the funding source
The funders had no role in the study design, data 
collection, data analysis, data interpretation, or in the 
writing of the manuscript. The corresponding author 
had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
We identified 9410 articles from the electronic searches, 
which reduced to 8386 after removing duplicates and to 
182 after screening of the title and abstract (figure 1). 
After a full-text review, seven articles were included in 
the systematic review, which increased to eight following 
review of reference lists (figure 1).
The eight eligible studies were published between 
1997 and 2016 and included 2786 participants from seven 
countries in Africa,7,14–17 South America,18 and Asia19,20 
(table). Seven studies evaluated participants in hospital 
settings or in clinics specialised in care of patients with 
HIV and tuberculosis. Two studies recruited only 
participants who were HIV-positive and one was restricted 
to participants who were HIV-negative. In all studies, the 
trial of antibiotics was used in a pre-screened population 
who tested tuberculosis-negative by smear microscopy. In 
addition to microscopy, three studies required a chest 
radiograph, but each of these excluded patients on the 
basis of a different radiographical finding: either features 
that were consistent with acute pneumonia,17 suggestive 
of respiratory diseases other than tuberculosis or other 
pathologies such as cardiac disorders,7 or suggestive of 
tuberculosis.14 Six studies used MTB culture as their 
reference diagnostic test, with samples collected from 
smear-negative participants at baseline, before antibiotics 
were prescribed. The remaining two studies15,20 first 
prescribed antibiotics to smear-negative participants at 
baseline and then collected sputum for a combination of 
MTB culture and smear microscopy (the reference 
standard) on the same day as evaluation for treatment 
response (index test outcome).
The choice of antibiotics for the trial of antibiotics 
varied across the studies, and four studies used more 
than one type of antibiotic. The most common class in 
the eight studies was penicillin, reported in six of the 
eight studies (table). Other antibiotic classes included 
macrolides in three studies, tetracyclines in two, and 
cephalosporins in one. The duration of treatment was 
also variable, ranging from 5 days to 14 days. Participants 
were assessed for their response to antibiotic treatment 
between 5 days and 14 days from the start of treatment. 
Although most studies implemented a single course of 
antibiotic treatment, two of them used two courses. 
One of these studies involved assessing the response to 
treatment before prescribing the second course,7 whereas 
the other study asked participants to return for assess-
ment only after completing both courses.19
There was no consistent definition of the response 
to treatment, and approaches ranged from using 
self-reported improvement to using a combination of 
clinical and radiological assessments (table). The 
approaches for measuring the response to treatment were 
largely subjective in all studies. One study included in their 
definition for the outcome “a negative smear on day 14”.19 
The treatment response evaluation approaches were more 
rigorous in studies involving hospitalised parti cipants. For 
example, Wilkinson and colleagues7 used changes in 
cough, the amount of sputum pro duced, and body 
temperature as reported by a nurse. One study did not 
report how response to treatment was assessed.17
All eight studies had disaggregated data, which allowed 
estimation of the pooled sensitivity and specificity of the 
trial of antibiotics compared with a mycobacteriology 
reference (MTB culture, smear microscopy, or both). The 
unadjusted individual study estimates for both specificity 
and sensitivity were not consistent across the studies 
Figure 1: Study selection
1024 duplicates excluded
8204 excluded on titles and abstracts
175 excluded 
173 did not provide differentiated data for 
index test (trial of antibiotics)
1 case series with 4 patients
1 systematic review
1 article identified from reference lists
8386 identified for title and abstract screen
182 full-text articles assessed for eligibility
8 studies included in analysis 
9410 articles identified through systematic database search
2963 in MEDLINE
3879 in Embase
2568 in Global Health
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(figure 2). Point estimates for sensitivity in the eight 
studies ranged from 15% to 97% (sample size range three 
to 235; median 56) and for specificity ranged from 
41% to 96% (sample size range 66 to 905; median 188). 
Compared with mycobacteriology tests, the pooled 
sensitivity of the trial of antibiotics was 67% 
(95% CI 42–85; I²=96%) and the pooled specificity was 
73% (58–85; I²=99%). The area under the summary 
receiver operating characteristic curve was 0·77 (95% CI 
0·73–0·80; figure 3).
In subgroup analyses, pooled estimates of sensitivity 
and specificity by study setting and reference standard 
definition still showed substantial heterogeneity 
(appendix p 12), although these analyses should be 
interpreted with caution because of the small number of 
included studies. Sensitivity was lower and specificity 
higher in studies that used MTB culture alone for the 
reference standard, although again these need to be 
interpreted with caution considering the small numbers. 
Fagan’s nomogram showed that if the prevalence of 
pulmonary tuberculosis is 20%, the trial of antibiotics 
would increase the probability of correctly detecting 
mycobacteriology-positive pulmonary tuberculosis in the 
study population by an absolute value of 19% (from a pre-
test probability of 20% to a post-test probability of 39%). 
When participants reported resolution of symptoms after 
a course of antibiotics (ie, testing tuberculosis-negative 
for the trial of antibiotics), the probability that they could 
nonetheless have mycobacteriology-positive pulmonary 
tuberculosis was 10% (appendix p 5). The Deeks’ funnel 
plot for the eight studies included in our meta-analysis 
indicated that there was no evidence of publication 
bias (p=0·84 for Deeks’ funnel plot asymmetry test; 
appendix p 11).
Studies within the 95% confidence bounds of the 
median distribution in the bagplot were not clustered 
together (appendix p 6). There were two outliers (the 
2006 study in Guinea15 and the 2012 study in Kenya),14 but 
excluding these studies from the meta-analysis in a post-
hoc sensitivity analysis did not account for the substantial 
heterogeneity of the full model (appendix p 12). Of note, 
the 2012 Kenya study categorised outcomes of antibiotic 
treatment as either complete resolution, partial resolution, 
or no resolution (table) and considered only complete 
(not partial) resolution as improvement. However, to be 
consistent with the definitions used in the other eligible 
studies, we re-categorised the data from the 2012 Kenya 
study such that clinical improvement referred to any 
improvement (either partial or complete resolution) and 
no improvement referred to no resolution. Using the 
authors’ definitions did not significantly change the 
pooled estimates for sensitivity and specificity.
Evaluating our main question (of the diagnostic 
accuracy of the trial of antibiotics compared with sputum 
mycobacteriology tests for the diagnosis of tuberculosis) 
against the eight studies, we established that each study 
had a potential risk of bias in at least one of the four 
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domains of the QUADAS-2 tool (appendix pp 7–10). A 
sensitivity analysis that involved doing the meta-analysis 
without the one study that showed a high risk of bias in 
at least three QUADAS-2 domains yielded sensitivity, 
specificity, and I² estimates that were similar to the full 
analysis (appendix p 12). In all studies, the patient 
selection process and conduct of both index and reference 
tests matched the expectation of our main question.
Discussion
We report, to our knowledge, the first systematic review 
to assess rigorously the diagnostic performance of the 
trial of antibiotics against mycobacteriology for sputum-
negative tuberculosis. Our main findings are that the 
available evidence base is insufficient and limited by 
incomplete geographical coverage and inconsistencies 
on the choice of antibiotics, duration of treatment, and 
case definition for post-treatment clinical improvement. 
However, the pooled sensitivity (67%) and specificity 
(73%) estimates fall well below minimum recom-
mendations for new tuberculosis triage and diagnostic 
tests for adults.21 As the medical community moves 
towards meeting End TB goals,22 clinicians and those 
designing public health programmes need to be aware of 
how substantial the misclassification by trial of antibiotics 
can be.
Our results call for reconsideration of the appro-
priateness of retaining routine trial of antibiotics in any 
international guidelines and national tuberculosis 
diagnostic algorithms. Algorithms that instead promote 
mycobacteriology and early chest radiography, repeated 
as needed, are likely to have better diagnostic accuracy.23 
Broad-spectrum antibiotics will still be needed to treat 
clinically suspected bacterial infection, with the crucial 
evidence gap then being how different antibiotic 
strategies affect clinical outcomes24 and antimicrobial 
resistance25 during tuberculosis investigation, including 
among key subgroups such as inpatients, people living 
with HIV, children, and participants identified through 
tuberculosis screening initiatives.
We identified only eight published studies investigating 
the diagnostic performance of the trial of antibiotics 
for tuberculosis, which is well below the number needed 
for making informed health-care choices. This number is 
especially striking given that tuberculosis is a 
life-threatening illness and that the trial of antibiotics 
Figure 2: Diagnostic sensitivity and specificity of the trial of antibiotics versus mycobacteriology tests
Meta-analysis of the diagnosis of pulmonary tuberculosis in the eight studies included. Mycobacteriology tests included culture only or culture plus smear microscopy. Dashed vertical lines show the 
pooled estimates. TP=true positive. FN=false negative. FP=false positive. TN=true negative.
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Figure 3: SROC meta-analysis of the diagnostic performance of the trial of 
antibiotics against reference mycobacteriology tests for diagnosing 
pulmonary tuberculosis in eight studies 
Area under the SROC is 0·77 (95% CI 0·73–0·80). Mycobacteriology tests included 
culture only or culture plus smear microscopy. The confidence contour shows the 
range that is likely to contain the population summary operating point and the 
prediction interval is the range that is likely to contain where study data that are 
not yet observed would fall. SROC=summary receiver operating characteristic 
curve.
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might be the most commonly used tuberculosis 
diagnostic test globally,26 resulting in non-pathogen-
directed prescription of tens of millions of doses of 
antibiotics each year.27 Consistent data from well 
performed randomised controlled trials are required for 
high-quality evidence,28 but our review did not identify 
any randomised controlled trials, and most of the 
observational studies that we identified were not optimally 
designed or sized. Instead, four of the eight studies 
included in this Article assessed the diagnostic 
performance of the trial of antibiotics as a secondary or 
exploratory outcome using a small subset of the original 
study population, reducing power and increasing the risk 
of selection bias. Methodological concerns are highlighted 
by the suboptimal scores for each included study on the 
QUADAS-2 tool for assessing risk of bias. The thin 
evidence and poor methodological quality that we have 
observed with the trial of antibiotics does not match the 
past 10 years’ rapid accumulation of high-quality trial data 
informing the rational use of antibiotics for the treatment 
of presumed chest infections when tuberculosis is not 
under consideration.29
The poor diagnostic performance reported here is 
unsurprising given the wide differential of tuberculosis 
symptoms, including viral and non-infectious causes.30 
Misleading responses could also arise from partial response 
to antibiotics in patients with tuberculosis with concurrent 
bacterial infections. This situation is best described in (but 
not limited to) patients with HIV, which led to the 
2007 WHO recommendation to separately investigate and 
manage tuberculosis and bacterial infections in people 
living with HIV.9 Misclassifying tuberculosis is costly 
to both the patient and the health system. False-positive 
tuberculosis diagnoses expose patients to unnecessary 
tuberculosis chemotherapy and its associated toxicity, 
stigma, hospital visits, lost schooling or employment, and 
any consequences from delayed diagnosis of the true cause 
of illness. False-negative tuberculosis diagnoses are 
associated with the individual and public health con-
sequences of delayed diagnosis and ongoing transmission.31
A framework for evaluating the diagnostic performance 
of the trial of antibiotics is provided by comparing our 
estimates against target product profiles for new 
non-sputum tuberculosis triage tests (minimum sensitivity 
of 90% and specificity of 70%) and sputum-based 
replacements for smear microscopy at the primary care 
level (minimum sensitivity of 60% for smear-negative 
tuberculosis and specificity of 98%).21 Additional attributes 
of diagnostic tests that are important to patients and are 
not met by the trial of antibiotics include timely diagnosis5,7 
and low cost (the recommendation from WHO21 of <US$6 
for a new diagnostic will be exceeded with the trial of 
antibiotics once expenses incurred by patients,32 costs of 
drugs, and staff time33 are included). The main attributes 
that are likely to drive the continued use of the trial of 
antibiotics globally are, therefore, the ease with which 
prescription fits into the high throughput of consulting 
rooms, as well as patients’ expectations and clinicians’ 
habitual pres cription of antibiotics for respiratory con-
sultations—considerations that should be discouraged and 
not encouraged in an era of rising threat from antimicrobial 
resistance.34–36
Our meta-analysis showed substantial heterogeneity, 
which is consistent with the non-standardised nature of 
choice and duration of antibiotics and the definition 
of response to treatment. Other variables potentially 
affecting heterogeneity include site-specific factors, such 
as antibiotic resistance patterns and exposure to tobacco 
smoke and air pollution, level of health care, pre-study 
investigations (eg, whether chest radiography was done), 
and HIV prevalence. The small number of eligible studies 
limited our power to explore these variables. Altogether, 
the heterogeneity in and underlying differences between 
studies highlight the variations that exist in the inter-
pretation of WHO guidelines in different settings.
The main limitations of this systematic review and 
meta-analysis are the small number of studies identified, 
the suboptimal number of participants per study, the 
pronounced variation in the definitions and methods 
used, and the suboptimal reference standard. Suboptimal 
reference standards are a concern for studies in tuber-
culosis diagnostics.37 The studies included in our 
review used either one or a combination of MTB culture 
and smear microscopy, each of which can misclassify 
patients’ tuberculosis disease status, thereby mis-
interpreting the true sensitivity and specificity of the trial 
of antibiotics. We were unable to explore the probable 
causes of heterogeneity given the data limitations. We 
restricted our search strategy to peer-reviewed articles 
and will therefore have omitted eligible studies published 
in conference proceedings or in programme reports. We 
might also have missed some articles, including peer-
reviewed papers, because data on trials of antibiotics are 
often reported as secondary or exploratory outcomes to 
the main study objective. In addition, the result of the 
Deeks’ funnel plot should be interpreted with the 
understanding that the model works best if it has at least 
ten studies. In the absence of a better tool, we thought 
that Deeks’ funnel plot could still give a reasonable 
estimate for publication bias.
The End TB Strategy calls for major expansion of 
tuberculosis testing to find the missing millions of 
undiagnosed tuberculosis cases and to save lives; making 
treatment available to the target of 40 million tuberculosis 
cases by 2022 will involve testing up to 1 billion people. 
The ethical obligation to minimise individual harms is 
especially pertinent in the context of systematic screening 
strategies, in which patients have not initiated the 
diagnostic process.38 Studies investigating the role, if any, 
of the trial of antibiotics in patients identified through 
systematic screening are missing from this meta-analysis 
but are urgently needed, both to minimise individual 
harms and from the equally important perspective of 
antibiotic stewardship.
For more on the WHO End TB 
Strategy see https://www.who.
int/tb/strategy/end-tb/en/
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In conclusion, despite more than 30 years of inter-
national guidelines and national algorithms promoting 
the trial of antibiotics for tuberculosis diagnosis, the 
small amount of data presented here on its diagnostic 
utility do not support the underlying rationale. Anti-
biotics might still be indi cated for the treatment of 
suspected bacterial infections, but in line with strategies 
for addressing antimicrobial resistance, their use during 
tuberculosis investigations should otherwise be mini-
mised. More data are needed to guide the mini misation 
of antibiotic use as we scale up tuberculosis testing 
globally. We urge donors to prioritise support for well 
conducted implementation research studies and rando-
mised controlled trials that aim to evaluate rigorously the 
effect of different antibiotic strategies on outcomes such 
as short-term mortality, need for hospitalisation 
or so-called rescue antibiotics, and anti microbial resis-
tance. These studies should include trials of the safety of 
antibiotic mini misation protocols29 to support the rapid 
generation of sufficient data to guide evidence-based, 
patient-centred management of presumptive tuberculosis 
patients, including key sub groups and populations for 
whom the relative benefits and harms of antibiotics are 
likely to vary from routine clinic adults—notably, young 
children, people with HIV,39 people with diabetes, and 
tuberculosis screening participants.
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